BNTX - BioNTech SE

NasdaqGS - NasdaqGS Real Time Price. Currency in USD

BioNTech SE

An der Goldgrube 12
Mainz 55131
Germany
49 6131 9084 0
http://www.biontech.de

SectorHealthcare
IndustryBiotechnology
Full Time Employees

Key Executives

NameTitlePayExercisedYear Born
Prof. Ugur Sahin M.D.Co-Founder, CEO & Member of Management BoardN/AN/A1965
Prof. Christoph Hubert HuberCo-Founder & Member of Supervisory BoardN/AN/A1944
Dr. Sierk PöttingCFO, COO & Member of Management BoardN/AN/A1973
Mr. Sean MarettChief Bus. Officer, Chief Commercial Officer & Member of Management BoardN/AN/A1965
Dr. Özlem TüreciChief Medical Officer & Member of Management BoardN/AN/A1967
Amounts are as of and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other diseases. The company is involved in developing FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 for prostate cancer; BNT113 that is in Phase I clinical trial to treat HPV+ head and neck cancers; BNT114, which is in Phase I clinical trial for triple negative breast cancer; and BNT115 and BNT116 to treat other cancers, including ovarian cancer. It also develops individualized neo-antigen specific immunotherapies, such as RO7198457, which is in Phase II clinical trial for first-line melanoma, as well as in Phase I clinical trial to treat multiple solid tumors; mRNA intratumoral immunotherapy comprising SAR441000 that is in Phase I clinical trial for solid tumors; and BNT141 and BNT142 to treat multiple solid tumors. In addition, the company develops RiboCytokines, which include BNT151, BNT152, and BNT152 for multiple solid tumors; chimeric antigen receptor T cell immunotherapies, such as BNT211 to treat multiple solid tumors, and BNT212 for pancreatic and other cancers; next-generation checkpoint immunomodulators consisting of GEN1046 and GEN1042, which are in Phase I clinical trial to treat multiple solid tumors. Further, it develops MVT-5873, an IgG1 monoclonal antibody, which is in Phase I clinical trial for pancreatic cancer; BNT411, small molecule immunomodulator product candidate for solid tumors; and infectious disease immunotherapies and rare disease protein replacement therapies. The company was founded in 2008 and is headquartered in Mainz, Germany.

Corporate Governance

BioNTech SE’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.